Machine learning prediction model of the treatment response in schizophrenia reveals the importance of metabolic and subjective characteristics.

Journal: Schizophrenia research
PMID:

Abstract

Predicting early treatment response in schizophrenia is pivotal for selecting the best therapeutic approach. Utilizing machine learning (ML) technique, we aimed to formulate a model predicting antipsychotic treatment outcomes. Data were obtained from 299 patients with schizophrenia from three multicenter, open-label, non-comparative clinical trials. For prediction of treatment response at weeks 4, 8, and 24, psychopathology (both objective and subjective symptoms), sociodemographic and clinical factors, functional outcomes, attitude toward medication, and metabolic characteristics were evaluated. Various ML techniques were applied. The highest area under the curve (AUC) at weeks 4, 8 and 24 was 0.711, 0.664 and 0.678 with extreme gradient boosting, respectively. Notably, our findings indicate that BMI and attitude toward medication play a pivotal role in predicting treatment responses at all-time points. Other salient features for weeks 4 and 8 included psychosocial functioning, negative symptoms, subjective symptoms like psychoticism and hostility, and the level of prolactin. For week 24, positive symptoms, depression, education level and duration of illness were also important. This study introduced a precise clinical model for predicting schizophrenia treatment outcomes using multiple readily accessible predictors. The findings underscore the significance of metabolic parameters and subjective traits.

Authors

  • Eun Young Kim
    Department of Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Jayoun Kim
    Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Korea.
  • Jae Hoon Jeong
    Department of Plastic and Reconstructive Surgery, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, Republic of Korea. psdrj2h@gmail.com.
  • Jinhyeok Jang
    Electronics and Telecommunications Research Institute (ETRI), Daejeon, Republic of Korea.
  • Nuree Kang
    Department of Psychiatry, Gyeongsang National University Hospital, Jinju, Republic of Korea.
  • Jieun Seo
    Department of Statistics, Ewha Womans University, Seoul, Republic of Korea.
  • Young Eun Park
    Department of Statistics, Ewha Womans University, Seoul, Republic of Korea.
  • Jiae Park
    Department of Statistics, Ewha Womans University, Seoul, Republic of Korea.
  • Hyunsu Jeong
    Department of Psychiatry, Seoul National University Hospital, Seoul, Republic of Korea.
  • Yong Min Ahn
    Institute of Human Behavioral Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; Department of Psychiatry, Seoul National University Hospital, Seoul, Republic of Korea. Electronic address: aym@snu.ac.kr.
  • Yong Sik Kim
    Department of Psychiatry, Dongguk University International Hospital, Goyang, Republic of Korea.; Institute of Clinical Psychopharmacology, Dongguk University College of Medicine, Goyang, Republic of Korea.
  • Donghwan Lee
    Department of R&D Center, Arontier Co., Ltd, Seoul, Republic of Korea.
  • Se Hyun Kim
    Department of Psychiatry, Dongguk University International Hospital, Goyang, Republic of Korea.; Institute of Clinical Psychopharmacology, Dongguk University College of Medicine, Goyang, Republic of Korea.